

Comparison of treatment recommendations formulated by APPRAISE-RS/TDApp, a prototype of automated, personalized, participatory recommender system, and clinical practice guidelines in a sample of simulated ADHD patients

Xavier Castells¹, Evgenia Baykova², Òscar Raya³, Domènec Serrano², Sacramento Mayoral², Ruth Cunill⁴, Marc Saez⁵, Carme Carrion⁶, David Rigau⁷, Beatriz López³.

Correspondance: xavier.castells@udg.edu

¹TransLab Research Group, Dept. of Medical Sciences, University of Girona, Girona, Spain; ²Institute of Health Care (ICS-IAS), Girona, Spain; ³eXIT research group of University of Girona, Spain; ⁴Sant Joan de Déu-Numància Health Park, Barcelona, Spain; ⁵Research Group on Statistics, Econometrics and Health (GRECS), University of Girona, Spain and CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain; ⁶eHealth Lab Research Group, School of Health Sciences, eHealth Center, Universitat Oberta de Catalunya, Spain; ⁷Cochrane Iberoamérica, Barcelona, Spain.

Introduction

Clinical practice guidelines (CPG) have several limitations that undermine their validity and utility in the clinical practice namely: obsolescence, lack of applicability of recommendations to many patients and little patient participation. As a result of these limitations, adherence to

CPGs recommendations is low. Artificial intelligence can help to overcome CPG limitations. We have recently developed APPRAISE-RS/TDApp (www.tdapp.org), an eHealth tool that formulates updated, personalized and participatory recommendations.

Objectives

To determine the degree of disagreement between treatment recommendations formulated by APPRAISE-RS/TDApp, a prototype of automated, personalized, participatory recommender system, and recent CPG in patients with attention deficit hyperactivity disorder (ADHD).

Methods

We have recently designed APPRAISE-RS; a recommender system development methodology that adapts the GRADE heuristic to formulate automated, up-to-date, participatory and personalized therapeutic recommendations. We have initially applied APPRAISE-RS to ADHD (APPRAISE-RS/TDApp). APPRAISE-RS/TDApp was tested on 28 simulated ADHD patients, 20 of which were children or adolescents and 8 were adults, 15 had a severe ADHD, 18 had a comorbid disorder and 6 were receiving concomitant medications.

The treatment recommendations formulated for these patients by 4 recent CPGs (USA, Canada, United Kingdom and Spain) were extracted. We determined the degree of disagreement between APPRAISE-RS/TDApp and CPGs' recommendations by computing the pharmacological distance (minimum and maximum 0,0 and 3,0 respectively) using the NbN2R ontology that was then applied to draw hierarchical clustering dendrograms.

Results

	N
Sample size	28
Children/adolescents	20
Comorbid disorder	18
Oppositional defiant disorder	4
Dyslexia	1
Major depressive disorder	1
Bipolar disorder	1
Autism	1
Tics	2
Borderline personality disorder	1
Anorexia nervosa	2
Tobacco use disorder	5
Cannabis use disorder	1
Epilepsy	1

The number of different recommendations using APPRAISERS/TDApp was 20, 3 using USA CPG, 7 using Canadian CPG and 4 using both the Spanish and UK GPGs.




Figure 1: Dendrograms showing that ADHD CPGs recommendations clustered on one side and APPRAISE-RS/TDApp on the other one in ADHD children (left) and adults (right). Y-axis: NbN2R -based pharmacological distance between CPGs and APPRAISE-RS Tdapp (X-axis).

Discussion

- APPRAISE-RS/TDApp provides treatment recommendations that are different from CPGs' and thus might be a tool for assisting medical decision-making.
- This promising results should encourage the conduction of a clinical study (<https://clinicaltrials.gov/ct2/show/NCT04228094>).

Funding

This work received funding from Fundació Pascual i Prats i el Campus Salut de la Universitat de Girona (AIN2018E), and joint funding from the European Regional Development Fund (ERDF), the Spanish Ministry of the Economy, Industry and Competitiveness (MINECO) and the Carlos III Research Institute, under grant no. PI19/00375. The work was carried out with support from the Generalitat de Catalunya 2017 SGR 1551.